Karyopharm Therapeutics downgraded by H.C. Wainwright
$KPTI
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright downgraded Karyopharm Therapeutics from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/10/2026 | $28.00 | Buy | Rodman & Renshaw |
| 2/5/2026 | Overweight | Cantor Fitzgerald | |
| 10/13/2025 | $15.00 | Neutral → Buy | H.C. Wainwright |
| 7/16/2025 | Buy → Neutral | H.C. Wainwright | |
| 7/11/2025 | $27.00 | Buy | H.C. Wainwright |
| 1/19/2023 | $8.00 | Overweight | Piper Sandler |
| 11/4/2022 | $7.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 3/8/2022 | $12.00 → $8.00 | Sector Perform | RBC Capital |
Rodman & Renshaw initiated coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $28.00
Cantor Fitzgerald initiated coverage of Karyopharm Therapeutics with a rating of Overweight
H.C. Wainwright upgraded Karyopharm Therapeutics from Neutral to Buy and set a new price target of $15.00
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will participate in a virtual fireside chat hosted by Cantor on June 8, 2026 at 12:00 p.m. ET. The event will feature the Company's senior management team and Robert Coleman, MD, FACOG, FACS, a globally recognized gynecologist oncologist and Principal Investigator of the Phase 3 XPORT-EC-042 trial.Institutional investors interested in attending the live event should contact their Cantor representative. A replay of this event will be available on June 8, 2026 at approximately 2:00pm ET under "Events and Pre
– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival –– Selected by EHA's Scientific Program Committee as One of the Top Abstracts to be Presented – NEWTON, Mass., June 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its late-breaking abstract was accepted for an oral presentation at the 2026 European Hematology Association (EHA) Congress, taking place June 11 to 14 in Stockholm, Sweden. The SENTRY presentation was selected by EHA's Scientific Program
– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib, with a Consistent SVR35 Benefit Observed Across Prespecified Subgroups –– Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline; Reductions in Symptoms Were Consistent Across Each Domain –– Promising Overall Survival Signal with >50% Reduction of Risk of Death versus Ruxolitinib, with Early Separation of the Kaplan-Meier Curves –– Evidence of Potential Disease Modification with More Patients Achieving ≥20% Reductions in VAF as Early as Week 24 versus Ruxolitinib – NEWTON, Mass., June 2, 2026 /PRNewswire/ -- Karyopharm The
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
S-8 - Karyopharm Therapeutics Inc. (0001503802) (Filer)
S-8 - Karyopharm Therapeutics Inc. (0001503802) (Filer)
NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. "Lori is an outstanding addition to the Karyopharm team," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow
NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. "We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs wi
NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t
– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial –– Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET –NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will host a conference call on June 2, 2026 at 2:00 p.m. ET featuring the Company's senior management team and Dr. John Mascarenhas, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and principal investigator of the Phase 3 SENTRY trial. The cal
– Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 –– Phase 3 SENTRY Results Selected for Late-Breaking Oral Presentation at ASCO on June 2 –– Total Revenue was $35.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $29.2 Million for the First Quarter of 2026 –– Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million –– Conference Call Scheduled for Today at 8:00 a.m. ET –NEWTON, Mass., May 14, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering n
-- Conference Call Scheduled for Thursday, May 14, 2026, at 8:00 a.m. ET --NEWTON, Mass., May 7, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, May 14, 2026, to discuss the financial results and other company updates.To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Ther
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)